GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved QLETLI ® (格乐立 ® ) for all eligible indications of the reference product, Humira ® (adalimumab)...
Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2019 American Association for Cancer Research ("AACR") Annual Meeting taking place March 2...
Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina Phase III clinical study for its tocilizumab biosimilar, BAT1806. Bio-Thera’s Phase III clinical trial will compare the safety and efficacy of BAT1806 and the reference product, Genentech’s Ro...
